دورية أكاديمية
أعرض في EDS

Corynebacterium pseudotuberculosis cp09 mutant and cp40 recombinant protein partially protect mice against caseous lymphadenitis.

التفاصيل البيبلوغرافية
العنوان: Corynebacterium pseudotuberculosis cp09 mutant and cp40 recombinant protein partially protect mice against caseous lymphadenitis.
المؤلفون: Silva JW; Technology and Research Institute, Tiradentes University, Av. Murilo Dantas, 300, Aracaju, Sergipe, 49032-490, Brazil. judsonall_16@hotmail.com., Droppa-Almeida D; Technology and Research Institute, Tiradentes University, Av. Murilo Dantas, 300, Aracaju, Sergipe, 49032-490, Brazil. danieladroppa@gmail.com., Borsuk S; Biotechnology Unit/Center for Technology Development, Federal University of Pelotas, Capão do Leão, Rio Grande do Sul, 96010-900, Brazil. sibeleborsuk@gmail.com., Azevedo V; Biological Sciences Institute, General Biology Department, Federal University of Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Minas Gerais, Belo Horizonte, Brazil. vascoariston@gmail.com., Portela RW; Health Sciences Institute, Federal University of Bahia, Avenida Reitor Miguel Calmon s/n, Salvador, BA, 40110-100, Brazil. rwportela@gmail.com., Miyoshi A; Biological Sciences Institute, General Biology Department, Federal University of Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Minas Gerais, Belo Horizonte, Brazil. miyoshi@icb.ufmg.br., Rocha FS; Biological Sciences Institute, General Biology Department, Federal University of Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Minas Gerais, Belo Horizonte, Brazil. flasouz@yahoo.com.br., Dorella FA; Biological Sciences Institute, General Biology Department, Federal University of Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Minas Gerais, Belo Horizonte, Brazil. fernandadorella@gmail.com., Vivas WL; Technology and Research Institute, Tiradentes University, Av. Murilo Dantas, 300, Aracaju, Sergipe, 49032-490, Brazil. lordelovivas@yahoo.com.br., Padilha FF; Technology and Research Institute, Tiradentes University, Av. Murilo Dantas, 300, Aracaju, Sergipe, 49032-490, Brazil. fpadilha@yahoo.com., Hernández-Macedo ML; Technology and Research Institute, Tiradentes University, Av. Murilo Dantas, 300, Aracaju, Sergipe, 49032-490, Brazil. lucyherma@hotmail.com., Lima-Verde IB; Technology and Research Institute, Tiradentes University, Av. Murilo Dantas, 300, Aracaju, Sergipe, 49032-490, Brazil. isabel_limaverde@yahoo.com.br.
المصدر: BMC veterinary research [BMC Vet Res] 2014 Dec 20; Vol. 10, pp. 965. Date of Electronic Publication: 2014 Dec 20.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101249759 Publication Model: Electronic Cited Medium: Internet ISSN: 1746-6148 (Electronic) Linking ISSN: 17466148 NLM ISO Abbreviation: BMC Vet Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, 2005-
مواضيع طبية MeSH: Bacterial Vaccines/*therapeutic use , Corynebacterium Infections/*prevention & control , Corynebacterium pseudotuberculosis/*genetics , Lymphadenitis/*prevention & control , Vaccines, Synthetic/*therapeutic use, Animals ; Cell Line, Tumor ; Cloning, Molecular ; Corynebacterium Infections/microbiology ; Corynebacterium pseudotuberculosis/immunology ; DNA, Bacterial/genetics ; Lymphadenitis/microbiology ; Mice/immunology ; Mice/microbiology ; Mice, Inbred BALB C ; Mutation/genetics ; Polymerase Chain Reaction
مستخلص: Background: Caseous lymphadenitis (CLA) is an infectious disease that affects small ruminants and is caused by Corynebacterium pseudotuberculosis. This disease is responsible for high economic losses due to condemnation and trim of infected carcasses, decreased leather and wool yield, loss of sales of breeding stock and deaths from internal involvement. Treatment is costly and ineffective; the most cost-effective strategy is timely immunisation. Various vaccine strategies have been tested, and recombinant vaccines are a promising alternative. Thus, in this study, different vaccine formulations using a recombinant protein (rCP40) and the CP09 live recombinant strain were evaluated. Five groups of 10 mice each were immunised with saline (G1), rCP40 (G2), CP09 (G3), a combination of CP09 and rCP40 (G4) and a heterologous prime-boost strategy (G5). Mice received two immunisations within 15 days. On day 30 after primary immunisation, all groups were challenged with a C. pseudotuberculosis virulent strain. Mice were monitored and mortality was recorded for 30 days after challenge.
Results: The G2, G4 and G5 groups showed high levels of IgG1 and IgG2a; G2 presented significant IgG2a production after virulent challenge in the absence of IgG1 and IgG3 induction. Thirty days after challenge, the mice survival rates were 20 (G1), 90 (G2), 50 (G3), 70 (G4) and 60% (G5).
Conclusions: rCP40 is a promising target in the development of vaccines against caseous lymphadenitis.
References: Vet Res. 2013;44:108. (PMID: 24219318)
Can J Vet Res. 1998 Jan;62(1):38-43. (PMID: 9442938)
Vet Res. 2013;44:54. (PMID: 23865568)
Vaccine. 2012 May 9;30(22):3311-9. (PMID: 22425788)
Appl Environ Microbiol. 2006 Nov;72(11):7368-72. (PMID: 16950910)
BMC Genomics. 2010;11:728. (PMID: 21192786)
Infect Immun. 1994 Jun;62(6):2562-7. (PMID: 8188379)
Braz J Med Biol Res. 2004 Aug;37(8):1103-9. (PMID: 15273812)
Mem Inst Oswaldo Cruz. 2011 Feb;106(1):32-7. (PMID: 21340352)
J Comp Pathol. 2007 Nov;137(4):179-210. (PMID: 17826790)
Infect Immun. 1999 Dec;67(12):6434-8. (PMID: 10569760)
Vet Res. 2014;45:28. (PMID: 24597857)
BMC Microbiol. 2008;8:228. (PMID: 19091138)
Vet Res. 2006 Mar-Apr;37(2):201-18. (PMID: 16472520)
Vet Immunol Immunopathol. 2008 Nov 15;126(1-2):131-41. (PMID: 18752855)
Vet Clin North Am Food Anim Pract. 2011 Mar;27(1):193-202. (PMID: 21215903)
Res Vet Sci. 2010 Feb;88(1):50-5. (PMID: 19665155)
World J Exp Med. 2013 Feb 20;3(1):1-10. (PMID: 24520540)
Infect Immun. 1998 Jun;66(6):2803-8. (PMID: 9596751)
Exp Parasitol. 2012 Apr;130(4):384-93. (PMID: 22343045)
Nat Rev Immunol. 2006 Apr;6(4):329-33. (PMID: 16557264)
المشرفين على المادة: 0 (Bacterial Vaccines)
0 (DNA, Bacterial)
0 (Vaccines, Synthetic)
تواريخ الأحداث: Date Created: 20141221 Date Completed: 20151120 Latest Revision: 20181113
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC4297461
DOI: 10.1186/s12917-014-0304-6
PMID: 25527190
قاعدة البيانات: MEDLINE
الوصف
تدمد:1746-6148
DOI:10.1186/s12917-014-0304-6